NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

Core Points - NRx Pharmaceuticals, Inc. will present at NobleCon21 on December 3rd, 2025, focusing on its expanded initiatives in investigational drugs and therapies for mental health conditions [1][2] - The company has begun generating clinical revenue and has made significant advancements in drug development since its last appearance at NobleCon in 2024 [2] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in Neuroplastic Therapies for central nervous system disorders, including suicidal depression, PTSD, anxiety, and Autism [5] - The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression and NRX-101 receiving Breakthrough Therapy Designation for suicidal bipolar depression [5] - NRx has filed an Abbreviated New Drug Application for its ketamine formulation, anticipating a launch in July 2026 [5] HOPE Therapeutics Overview - HOPE Therapeutics, a subsidiary of NRx, is establishing a network of interventional psychiatry clinics offering various therapies, including ketamine and transcranial magnetic stimulation [6] - The network is the first in Florida to provide the AMPA One Day (ONE-D) treatment, which combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine for treatment-resistant depression [6] Conference Details - Interested investors can attend the presentation at a discounted rate using a specific discount code [3] - A high-definition video webcast of the presentation will be available on the company's website and other platforms for 90 days following the event [4]